Advancing screening
with DocMemo
Discover how we identify memory concerns in the general population, and streamline trial recruitment
DocMemo: early detection and qualification of memory complaints
DocMemo is a digital pre-screening platform designed to identify memory complaints early, assess risk, and orient individuals toward appropriate care pathways or clinical trial participation. By reaching people before they enter traditional care systems, DocMemo addresses one of the main bottlenecks in neurological clinical development: finding the right patients early enough.
What DocMemo is
DocMemo is not a diagnostic tool. It is a large-scale, validated pre-screening solution that enables early signal detection, structured risk assessment, and informed orientation.
Through a simple and accessible digital experience, individuals can report cognitive concerns, complete structured assessments, and receive guidance based on their profile. For clinical research stakeholders, DocMemo creates a scalable, real-world entry point into populations that are otherwise difficult to reach.
Why DocMemo matters
For many neurodegenerative diseases, the window for effective intervention is early. Yet most patients enter care late, and clinical trials struggle to identify suitable participants in time. DocMemo shifts this paradigm by enabling:
- Earlier identification of at-risk individuals
- Better alignment between patients, care pathways, and research opportunities
- Faster, more efficient recruitment for trials
Who DocMemo is for
DocMemo creates value across the clinical development ecosystem:
- Sponsors: Access to earlier, better-characterized patient populations for clinical trials
- Clinical sites: A continuous flow of pre-qualified participants
- Healthcare systems and partners: Structured orientation of individuals toward appropriate care
- Individuals: Clear guidance, informed choices, and access to research opportunities
From pre-screening to clinical execution
DocMemo is designed to integrate seamlessly with downstream clinical and research workflows. Individuals who meet predefined criteria can be referred to participating sites for further evaluation or trial participation, while others are oriented toward appropriate care options.
In 2025 alone, DocMemo profiled and oriented nearly 40,000 individuals across Europe and the United States and actively supported recruitment for large Phase 2 and Phase 3 trials in the US.
Built for scale, validation, and trust
DocMemo is built on scientifically validated instruments and models, and designed with operational and regulatory realities in mind. Privacy, data protection, and ethical considerations are central to the platform, ensuring responsible use at scale.
By combining early detection, structured qualification, and real-world deployment, DocMemo turns early signals into actionable pathways — for patients, clinicians, and clinical research.